Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;4(4):e5184.
doi: 10.1371/journal.pone.0005184. Epub 2009 Apr 17.

Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors

Affiliations

Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors

Elise Heuvelin et al. PLoS One. 2009.

Abstract

Objectives: Soluble factors released by Bifidobacterium breve C50 (Bb) alleviate the secretion of pro-inflammatory cytokines by immune cells, but their effect on intestinal epithelium remains elusive. To decipher the mechanisms accounting for the cross-talk between bacteria/soluble factors and intestinal epithelium, we measured the capacity of the bacteria, its conditioned medium (Bb-CM) and other Gram(+) commensal bacteria to dampen inflammatory chemokine secretion.

Methods: TNFalpha-induced chemokine (CXCL8) secretion and alteration of NF-kappaB and AP-1 signalling pathways by Bb were studied by EMSA, confocal microscopy and western blotting. Anti-inflammatory capacity was also tested in vivo in a model of TNBS-induced colitis in mice.

Results: Bb and Bb-CM, but not other commensal bacteria, induced a time and dose-dependent inhibition of CXCL8 secretion by epithelial cells driven by both AP-1 and NF-kappaB transcription pathways and implying decreased phosphorylation of p38-MAPK and IkappaB-alpha molecules. In TNBS-induced colitis in mice, Bb-CM decreased the colitis score and inflammatory cytokine expression, an effect reproduced by dendritic cell conditioning with Bb-CM.

Conclusions: Bb and secreted soluble factors contribute positively to intestinal homeostasis by attenuating chemokine production. The results indicate that Bb down regulate inflammation at the epithelial level by inhibiting phosphorylations involved in inflammatory processes and by protective conditioning of dendritic cells.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Bb and its soluble factors dampen TNFα-induced cytokine secretion in epithelial cells.
A. After 4 hour-incubation of HT29-19A cells with TNFα±Bb (MOI 100) or Bb-CM, epithelial cell supernatants were tested by the Raybio® human cytokine array V (One representative array of two experiments). Secretion of chemokines (CXCL1, CXCL8, CCL4) and of other inflammatory molecules was inhibited in the presence of Bb and Bb-CM as judged by densitometric analysis. B. Long lasting inhibition (up to 7 hours) of CXCL8 secretion by Bb-CM (∼50%) was observed using ELISA. n = 7, *p<0.01 vs TNFα. C–D. HT29-19A cell monolayers were treated (4 hours) from the basolateral compartment with TNFα together with Bb or commensal bacteria (B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15) placed in the apical compartment at increasing MOI. As quantified by ELISA, Bb dose-dependently inhibited TNFα-induced CXCL8 secretion, in contrast to other bacteria. n = 11, †p<0.0001 ; *p<0.001 vs TNFα.
Figure 2
Figure 2. Bb preserves the integrity of HT29-19A epithelial cells.
Filter-grown HT29-19A monolayers were treated with 10 ng/ml TNFα with or without live Bb placed in the apical compartment for 4 h. As index of epithelial viability, we measured markers of apoptosis (M30) and epithelial tight junction integrity (ZO-1). After 4 hour-treatment with Bb, HT29-19A monolayers (Costar® clear 3460) were labelled with the monoclonal antibody M30 CytoDEATH recognizing caspase-cleaved cytokeratin 18 (1∶10, Roche Diagnostics) and rabbit polyclonal anti-ZO-1 (24 µg/ml, Zymed). Cells were observed with the laser scanning confocal microscope LSM 510 Carl Zeiss. Treatment with H2O2 (100 µM), used as a positive control, induced apoptosis (blue M30 labeling) and alteration of ZO-1 distribution (green). In contrast, in basal condition or after treatment with Bb at MOI 100, no M30 labeling was observed and ZO-1 distribution was preserved. Results are representative of three independent experiments.
Figure 3
Figure 3. Bb and its soluble factors inhibit TNFα-induced NF-κB in epithelial cells.
A. HT29-19A cells were incubated for 30 min with TNFα±Bb-CM and localization of the NF-κB p65 subunit was observed by confocal microscopy. Following exposure to TNFα, p65 (green) was translocated into the nuclei (blue) and co-localization was observed (white spots). Bb-CM inhibited TNFα-induced p65 subunit translocation. n = 3 independent experiments. B. HT29-19A cells were incubated for 4 hours with TNFα±Bb-CM. Electrophoretic migration shift assay (EMSA) was performed following extraction of nuclear proteins. TNFα condition was taken as 100% activation and Bb-CM induced a 40% inhibition of NF-κB activation (n = 2 independent experiments). C. Epithelial cells were incubated with TNFα±Bb at MOI 100. Activation of NF-κB was inhibited by ∼40% with Bb but not with commensal bacteria B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15. n = 2 independent experiments. D. HT29-19A cells were treated with TNFα±Bb-CM. Total proteins were separated by SDS-PAGE and revealed with antibodies to phospho-IκB-α, IκBα and β-actin. Bb-CM inhibited the TNFα-induced phosphorylation of IκB-α as early as 5 min and IκB-α degradation after 15 min. n = 3 independent experiments.
Figure 4
Figure 4. Bb and its soluble factors inhibit TNFα-induced phosphorylation of p38-MAPK in epithelial cells.
A–C. HT29-19A cells were incubated for 4 hours on the apical surface with live Bb or commensal bacteria B.breve ATCC 15698, L.rhamnosus 10863, E.rectale L15 at MOI 100, together with basolateral TNFα. Activation of AP-1 assessed by EMSA was inhibited by ∼35% in the presence of Bb-CM and by ∼40% in the presence of Bb, but not in the presence of other bacteria. n = 2 independent experiments. D. HT29-19A cells were treated with TNFα±Bb-CM. Total proteins were analysed by SDS-PAGE and revealed with antibodies to phospho-p38-MAPK, p38-MAPK and β-actin. Bb-CM inhibited TNFα-induced phosphorylation of p38-MAPK from 15 to 30 min of incubation. n = 3 independent experiments.
Figure 5
Figure 5. Protective effect of Bb and Bb-CM in TNBS-induced colitis in mice.
A. Wallace scores were used to semi-quantify colitis activity in BALB/c mice after colonic instillation of TNBS (control group) with or without intragastric pre-treatment with 108 CFU Bb (Bb i.g.), intraperitoneal injection of Bb-CM (Bb-CM i.p.), intraperitoneal injection of non treated-DC (DC) or Bb-CM conditioned-DC (DCBb -CM). The mild inhibition of colitis observed with Bb i.g. became significant with Bb-CM and DCBb -CM. B. Percentage protection in mice of the different groups compared to control (TNBS only). C. Quantitative RT-PCR analysis of mRNA expression of pro-inflammatory cytokines/mediators in the colon, 48 hours after TNBS-induced colitis with or without treatment. A significant inhibition of pro-inflammatory molecules in colonic mucosa (IL-1β, CXCL-1, IL-23, IL-6, COX2) was observed in the presence of Bb-CM or Bb-CM pre-conditioned DC. Scatter plots are presented with medians. *p<0.05, †p<0.01 vs TNBS; n = 7 to 8 mice per group.

References

    1. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310–312. - PubMed
    1. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–309. - PubMed
    1. McCole DF, Barrett KE. Varied role of the gut epithelium in mucosal homeostasis. Curr Opin Gastroenterol. 2007;23:647–654. - PubMed
    1. Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann N Y Acad Sci. 2006;1072:351–355. - PubMed
    1. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174:4453–4460. - PubMed

Publication types

LinkOut - more resources